MedTrace Logo

Systematic Early Use of Neuromuscular Blocking Agents in ARDS Patients

NCT00299650 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 340

Last updated 2008-10-10

No results posted yet for this study

Summary

The use of neuromuscular blocking agents (NMBA) in ARDS patients has not been extensively investigated. The aim of the study is to show a reduction of the mortality rate of ARDS patients.

Conditions

  • ARDS

Interventions

DRUG

cisatracurium

DRUG

Placebo

physiological serum infusion

DRUG

Cisatracurium besilate

Cisatracurium besilate infusion (900mg/day)

Sponsors & Collaborators

  • GlaxoSmithKline

    collaborator INDUSTRY

  • Assistance Publique Hopitaux De Marseille

    lead OTHER

Principal Investigators

  • Laurent Papazian, MD · Assistance Publique Hôpitaux de Marseille

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-03-31
Primary Completion
2008-10-31
Completion
2008-10-31

Countries

  • France

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00299650 on ClinicalTrials.gov